John­son & John­son scored an ap­peals court win in its bid to block gener­ic com­pe­ti­tion for its long-act­ing schiz­o­phre­nia drug.

Mehmet Oz has com­mit­ted to de­fend­ing Medicare drug price ne­go­ti­a­tions in court if he is con­firmed to lead CMS.

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

When End­points News launched our Health Tech newslet­ter in Fall 2023, it was the first time our news­room had stepped out­side the world of bio­phar­ma … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Di­men­sion has crossed a key thresh­old. The VC firm’s trio of New York and Bay Area man­ag­ing part­ners has raised a sopho­more fund in the … ...

The Biden Ad­min­is­tra­tion said Wednes­day that it has se­cured agree­ments with Ver­tex Phar­ma­ceu­ti­cals and blue­bird bio for their sick­le cell dis­ease gene ther­a­pies ...

Now that Pres­i­dent-elect Don­ald Trump has made his choice for FDA com­mis­sion­er, re­ac­tions and analy­sis are pour­ing in from bio­phar­ma ex­ec­u­tives and for­mer staffers ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The Park­er In­sti­tute for Can­cer Im­munother­a­py, a re­search net­work es­tab­lished by tech en­tre­pre­neur Sean Park­er, an­nounced a new $125 mil­lion in­vest­ment.

CatalYm has racked up $150 mil­lion in an over­sub­scribed Se­ries D to ad­vance its an­ti­body drug that neu­tral­izes GDF15 — a tar­get pre­vi­ous­ly ex­plored by oth­er … ...